{"name":"Shanghai Junshi Bioscience Co., Ltd.","slug":"shanghai-junshi-bioscience-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":12,"colorKey":"immunology","drugs":[{"name":"Drug：JS001, Intravenous infusion","genericName":"Drug：JS001, Intravenous infusion","slug":"drug-js001-intravenous-infusion","indication":"Other","status":"phase_1"},{"name":"JS001 and JS004","genericName":"JS001 and JS004","slug":"js001-and-js004","indication":"Other","status":"phase_1"},{"name":"JS207 in combination with 9MW2821","genericName":"JS207 in combination with 9MW2821","slug":"js207-in-combination-with-9mw2821","indication":"Other","status":"phase_2"},{"name":"Biological：JS002","genericName":"Biological：JS002","slug":"biological-js002","indication":"Other","status":"phase_1"},{"name":"Cetuximab Solution for infusion","genericName":"Cetuximab Solution for infusion","slug":"cetuximab-solution-for-infusion","indication":"Other","status":"phase_1"},{"name":"JS005","genericName":"JS005","slug":"js005","indication":"Other","status":"phase_2"},{"name":"JS006 as Monotherapy","genericName":"JS006 as Monotherapy","slug":"js006-as-monotherapy","indication":"Other","status":"phase_1"},{"name":"JS207 for Injection","genericName":"JS207 for Injection","slug":"js207-for-injection","indication":"Other","status":"phase_2"},{"name":"JS212","genericName":"JS212","slug":"js212","indication":"Other","status":"phase_2"},{"name":"JS401","genericName":"JS401","slug":"js401","indication":"Other","status":"phase_1"},{"name":"Placebo for Tifcemalimab","genericName":"Placebo for Tifcemalimab","slug":"placebo-for-tifcemalimab","indication":"Other","status":"phase_3"},{"name":"Renvastinib","genericName":"Renvastinib","slug":"renvastinib","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"JS107 for Injection","genericName":"JS107 for Injection","slug":"js107-for-injection","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"JS002","genericName":"JS002","slug":"js002","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"JS004 in combination with toripalimab","genericName":"JS004 in combination with toripalimab","slug":"js004-in-combination-with-toripalimab","indication":"Advanced or metastatic solid tumors (Phase 3 development)","status":"phase_3"},{"name":"JS203 combined with lenalidomide","genericName":"JS203 combined with lenalidomide","slug":"js203-combined-with-lenalidomide","indication":"Relapsed or refractory multiple myeloma","status":"phase_2"},{"name":"Bendamustine or gemcitabine","genericName":"Bendamustine or gemcitabine","slug":"bendamustine-or-gemcitabine","indication":"Hematologic malignancies (lymphoma, leukemia)","status":"phase_3"},{"name":"Cisplatin for Injection / Carboplatin Injection","genericName":"Cisplatin for Injection / Carboplatin Injection","slug":"cisplatin-for-injection-carboplatin-injection","indication":"Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer)","status":"phase_3"},{"name":"Oxaliplatin for injection","genericName":"Oxaliplatin for injection","slug":"oxaliplatin-for-injection","indication":"Adjuvant treatment of stage III colon cancer","status":"phase_3"},{"name":"Placebo for toripalimab","genericName":"Placebo for toripalimab","slug":"placebo-for-toripalimab","indication":"Control arm in phase 3 trials of toripalimab for cancer indications","status":"phase_3"},{"name":"Tifcemalimab injection","genericName":"Tifcemalimab injection","slug":"tifcemalimab-injection","indication":"Non-small cell lung cancer","status":"phase_3"}]}],"pipeline":[{"name":"JS107 for Injection","genericName":"JS107 for Injection","slug":"js107-for-injection","phase":"phase_3","mechanism":"JS107 is a monoclonal antibody that targets and blocks PD-L1, enhancing anti-tumor immune responses by releasing the brakes on T-cell activation.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"Drug：JS001, Intravenous infusion","genericName":"Drug：JS001, Intravenous infusion","slug":"drug-js001-intravenous-infusion","phase":"phase_1","mechanism":"JS001 blocks the PD-1 receptor on T cells, preventing its interaction with PD-L1/PD-L2 ligands and restoring anti-tumor immune activity.","indications":[],"catalyst":""},{"name":"JS001 and JS004","genericName":"JS001 and JS004","slug":"js001-and-js004","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"JS002","genericName":"JS002","slug":"js002","phase":"phase_3","mechanism":"JS002 is a monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1/PD-L2) to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Hepatocellular carcinoma","Gastric cancer"],"catalyst":""},{"name":"JS004 in combination with toripalimab","genericName":"JS004 in combination with toripalimab","slug":"js004-in-combination-with-toripalimab","phase":"phase_3","mechanism":"JS004 is a CTLA-4 inhibitor that blocks immune checkpoint signaling, and when combined with toripalimab (a PD-1 inhibitor), it provides dual checkpoint blockade to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 development)"],"catalyst":""},{"name":"JS203 combined with lenalidomide","genericName":"JS203 combined with lenalidomide","slug":"js203-combined-with-lenalidomide","phase":"phase_2","mechanism":"JS203 is a PD-1 inhibitor","indications":["Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"JS207 in combination with 9MW2821","genericName":"JS207 in combination with 9MW2821","slug":"js207-in-combination-with-9mw2821","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bendamustine or gemcitabine","genericName":"Bendamustine or gemcitabine","slug":"bendamustine-or-gemcitabine","phase":"phase_3","mechanism":"This is a combination of two chemotherapy agents: bendamustine, which alkylates DNA and disrupts cell division, and gemcitabine, which inhibits ribonucleotide reductase and gets incorporated into DNA to cause chain termination.","indications":["Hematologic malignancies (lymphoma, leukemia)","Solid tumors (under investigation in phase 3)"],"catalyst":""},{"name":"Biological：JS002","genericName":"Biological：JS002","slug":"biological-js002","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Cetuximab Solution for infusion","genericName":"Cetuximab Solution for infusion","slug":"cetuximab-solution-for-infusion","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Cisplatin for Injection / Carboplatin Injection","genericName":"Cisplatin for Injection / Carboplatin Injection","slug":"cisplatin-for-injection-carboplatin-injection","phase":"phase_3","mechanism":"Cisplatin and carboplatin are platinum-based chemotherapy agents that bind to DNA and cause cross-linking, leading to cell death.","indications":["Various solid tumors (lung cancer, ovarian cancer, testicular cancer, bladder cancer, head and neck cancer)","Combination chemotherapy regimens for advanced malignancies"],"catalyst":""},{"name":"JS005","genericName":"JS005","slug":"js005","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"JS006 as Monotherapy","genericName":"JS006 as Monotherapy","slug":"js006-as-monotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JS207 for Injection","genericName":"JS207 for Injection","slug":"js207-for-injection","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JS212","genericName":"JS212","slug":"js212","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JS401","genericName":"JS401","slug":"js401","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Oxaliplatin for injection","genericName":"Oxaliplatin for injection","slug":"oxaliplatin-for-injection","phase":"phase_3","mechanism":"Oxaliplatin works by interfering with DNA replication in cancer cells, leading to cell death.","indications":["Adjuvant treatment of stage III colon cancer","First-line treatment of metastatic colorectal cancer"],"catalyst":""},{"name":"Placebo for Tifcemalimab","genericName":"Placebo for Tifcemalimab","slug":"placebo-for-tifcemalimab","phase":"phase_3","mechanism":"A placebo control arm that provides no active therapeutic effect, used as a comparator in clinical trials of Tifcemalimab.","indications":[],"catalyst":""},{"name":"Placebo for toripalimab","genericName":"Placebo for toripalimab","slug":"placebo-for-toripalimab","phase":"phase_3","mechanism":"Placebo is an inert substance with no active pharmacological mechanism.","indications":["Control arm in phase 3 trials of toripalimab for cancer indications"],"catalyst":""},{"name":"Renvastinib","genericName":"Renvastinib","slug":"renvastinib","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tifcemalimab injection","genericName":"Tifcemalimab injection","slug":"tifcemalimab-injection","phase":"phase_3","mechanism":"Tifcemalimab injection is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer","Melanoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNeC1xTV9JMmNIcnQ4aHp3NzBVakdyVngxWUZESUx4b2ZRRi1pR3VwVFlxdGVZVEE4dzVDTlptSWhleXMtc0NJdnBvNFMyWXlCak1EMGloXzFhQWFmRm91M3ZfdXlNTHhiQlVxbzNEUmQ5ejdPYXE3djhxZm1aMl95MjFxem1Bbjk3NVZwZVc0ODVOREdNX1RN?oc=5","date":"2026-03-20","type":"trial","source":"openPR.com","summary":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+ - openPR.com","headline":"Hepatic Tumor Clinical Trial Landscape Strengthens as 75+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQZmw1NkV3YVJnUldtcmItdS14ak4wMFN6dWN2SUFfVG5uTHN3dWt5ZFlOMzV5SnoxYVZuYnlsak1WeEhrZW85YXI4T2syOHNKZlNEZlR5Q29WRTBvazVEUHBqS2ZFdXpSdW9BWE1YVTkwWHZmNktITm1KNzlfdTVYWU11dHJTajRDamFWWklGN0s2VFVoMDBENjRDbnpjanBCWFlSWEFpYzRxNWNqaTY5R0tObw?oc=5","date":"2025-03-25","type":"earnings","source":"BioWorld News","summary":"Checkpoint inhibitor journey traces Chinese firms’ path to global revenue - BioWorld News","headline":"Checkpoint inhibitor journey traces Chinese firms’ path to global revenue","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQSDRlcTFteFU3MEkzSnNQdTRXV2RZMTZ4RGk1ZTkyblltZTI1SDBBWjkzUnhNVmpTRkM1dDk0YnA3VWlJcVZnQ0pMMllPQ3RkOENmYkRxYldTcVpLQkh6ZEYxWUVUSlNXWVZsS3ZnazZRR3BzSllPNUFvM1hTRXdudjZacm91QkFGWkluWlZOdThaLUpXU2QwVS1JV0dzdFZndVJHVHdEMVJ6UkpxVUUwUFdXRENxLUtOTjdSMGdqWHdrNUkwVTBPdjlQazB5Z3hjTktIbXROcmt0Uk5XNThfVnRYVF9KQlY2bVhCUW5sRGdXUVdiTE9pdGFVRy0xVVliNjNMZFRfblpfVkdsSENjQ2RLdThzczQ?oc=5","date":"2025-03-04","type":"regulatory","source":"PR Newswire UK","summary":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance | DelveInsight - PR Newswire UK","headline":"Ono's ROMVIMZA Approval Shakes Up Tenosynovial Giant Cell Tumors Market, Challenging Daiichi Sankyo's TURALIO Dominance ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQSGo5Q2pmXy1XS3NqWmVZZkhhejVDd1Q5VXFPc3AyR2xfTUVFM3BCcDNMTTlRTVNBV2dpUWNKclgwQk4tZGU5WEJ5WUVGb08xX2JKS2ZyeU16TE9IbzlBQUxpamxwMFVPTUpLMU5kSTBTX1ptTVVDSWVRb1pMVkVFLUFEbUNObEMycHh1RUdXd1hVTlBiT1ZQdGxhN2pyNnlpYy0yYk4tREx6Y1VVM1BFUGVGWl9MWU9tNmdkc3lnM3A3VGUyRGVoOFk1ZG0yaTltNzMxYVNILTd4Q2F6UDNWVkJrUG8tRGtFQmRCbWhKQ0ZPV2ZFRk1LSFVMWQ?oc=5","date":"2025-01-21","type":"regulatory","source":"BioPharma APAC","summary":"Junshi Biosciences Secures Australian Approval for Toripalimab, First Immuno-Oncology Treatment for Nasopharyngeal Carcinoma - BioPharma APAC","headline":"Junshi Biosciences Secures Australian Approval for Toripalimab, First Immuno-Oncology Treatment for Nasopharyngeal Carci","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPRDBUYWpfaWlPSG9fckdIVGtwM1QyVjdRME4wdWMxU0Vqd2FhT3lhTUZWTHF6QVdBTU5sTWEtTDJGMHhOWnRLN0VnYkN6OWdDZDdOQ3JuLWlOeFJzN2xLS2t5ZUdOYjBCWXpDcUFDUF8zSG9ZeVZleW0wSDdobUtTaFRNcHItbnV2ZUpJd0pvdHFnWWdwekJCZldySUwxVEY1QTZVcVdJdmNoNDRYbEVvRDZla21SRzBsd3ZWb202NUlyMW1VUGFGNDZHTW1HZ1JZQXRENNIB2gFBVV95cUxNRk1ia1pwOU1lOWdKMXpuaHk1WURMelE5cHRieVV2WjAxYnc3RDhZWjZnZnJiV19mYkFrcHRnX0lWRHJDRnJUajZ0bjBNd2t6VnRRRFBrTzBLSVdXSEhGckl2YW1ZSVZHWm9OR2dDOHhVaDROWXFQeFpCSlJZcFpsVWdod3V5ZFBXbFlFYTRXNkFtbGdZZWgtc0l1VzdTQ2prMUx4VWZWc3lvZzFNcWk5R0hDZkR4d2tKUTJ1NDJGRkcyOXp1d2RiWXEtQnBtU29BU2VFMjhXQS1ZZw?oc=5","date":"2024-11-29","type":"pipeline","source":"Business Standard","summary":"Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer - Business Standard","headline":"Dr. Reddy's up 2% on launching Toripalimab to treat nasopharyngeal cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQYXlpWWtJNGNLZHJEeWRMRnR6R0E2SVY5eElibzV2ZDlyaGZ0cDNLd3Z4V2hIVWpoZlA1LUw5SEd6SHRHbWNva1VQcUExU1FQN1lWV3pBN2M4aUktay16cGpCc2pPc2xsOWlwUzBvMXFGbmduaG5OdE1mZEM5aEdlN3BsNU1LNER4eWtScEpHb1hKUllUWm1OSndEM3MySmF6d3VPY0Q5ZVFjclBWUG5TMGNpODhhYWdiUlFQbV94T0g1T3RyZ2FnOWlhS0Z1c0xpNnExUGJBMTJfSGNGR01paGlveU5mazNqMV9JM1FIX1FlSzUwSjJ4VEtBWjVtWTVfTmpteW9n?oc=5","date":"2024-11-19","type":"regulatory","source":"PR Newswire","summary":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsight - PR Newswire","headline":"Systemic Lupus Erythematosus Clinical Trial Pipeline Gains Momentum as 120+ Key Companies at the Forefront | DelveInsigh","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBFUV80UWlsNU5nQnp4STZwaHBnbUhWTTBfNm9hcEdyNVA0SEM2LXFFYkh1V2IwTmZEMTZ5ZE9lWVh6TGNGaHhmV2pRekdJaE0yX0dkNjJxVEpHYkcxUUJrS3I1c3RDUkdYWEp3Z3pRc2pNX0VWZFc0UUtn?oc=5","date":"2024-10-28","type":"pipeline","source":"Straits Research","summary":"Immune Checkpoint Inhibitors Market Size, Global Trends, Share | Industry Report, 2033 - Straits Research","headline":"Immune Checkpoint Inhibitors Market Size, Global Trends, Share | Industry Report, 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPc3JVTVdiQ05RMW9lOTVzQUhETVZ6dW5vSUJXTExjOG1Rd25xaEpXamFhcV8zbU84YVlmTDZBb0dOYzJ3UEFPaXdNelZ3ZjZaZTBWbTcxd0pfQ0lIbWVOOHQ2LTREZ0xsdEhMZFZXWHBkSzVZNzBYS2FUU0JnQW54MjdVQm1kamVPY1VmQ3hNLU91TTRRWG4yU3R4a2FUTFZOemJySHBLQkRCVk1OYmkwRU5JWWR1NW54VTBNcUpR?oc=5","date":"2023-05-08","type":"deal","source":"Contract Pharma","summary":"Junshi Biosciences, Dr. Reddy’s Partner to Develop Toripalimab in 21 Countries - Contract Pharma","headline":"Junshi Biosciences, Dr. Reddy’s Partner to Develop Toripalimab in 21 Countries","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQemtXM0xTUVBZSnZYdEp4bm1veEFnNWNhSlR5eU1fc3dkbXhoVFhXMmVWZEV3dFpNUXVkNm5oT0xZaGdMZ09WbTljQ1Z4VmNxQU50b1Q4Tm52ZmdGQzhvbHphaXFnRkhselpLck9NM2w4aFVFczdBMS0wYmVxNVdBbF90azN1Y0h6SU8xcHdONzU1VnpDa2FXRVByUVZxalplX2Y4elY4aW1lYVBpMFllYW16cU9RWlE1NGVZcGF1Nk80Ym8xN0E?oc=5","date":"2023-03-30","type":"deal","source":"Contract Pharma","summary":"Junshi Biosciences, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia - Contract Pharma","headline":"Junshi Biosciences, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNSVhfendvcUMtWTlaN01yY2E1RzBjc0VfdXFFd1pfX2s4aUM0MDFMNmJvUmotaVhqS20wRHI3WmVvWGpkbXFneS1JRVF5aFpzc3VUYzNfQ0ZJSnV5NWVhQjBEUWFaSlhyUFIwUkt4YXhBMzc3LXVCM2N5cEYza0N0WWpIQmJvRk1JTFM2VVZZd1hRWFRiWldINGxxSXFhdGU3eUw1QnVDbXdOelFpQzZ6VXozVEJjYm83Vm0tQlcxbjctbm9CUkFRcVpn?oc=5","date":"2022-05-02","type":"regulatory","source":"Reuters","summary":"U.S. FDA declines to approve two more China-tested drugs - Reuters","headline":"U.S. FDA declines to approve two more China-tested drugs","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE51dmg2WDVDZnY0MG5LeFlVT0RTem1GMXdRZy1qVEN4VUdsNmMwZXE1VDZLR2JuamkxLVc3Vm9sNTVCakVtTVBFbjZYMGY1TWhEaEpUQnh3?oc=5","date":"2018-12-18","type":"pipeline","source":"sg.finance.yahoo.com","summary":"Shanghai Junshi Biosciences Co., Ltd. (1877.HK) stock price, news, quote and history - sg.finance.yahoo.com","headline":"Shanghai Junshi Biosciences Co., Ltd. (1877.HK) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBDS2p6ZEtDNk1jaEpWUWEwaEt6Q0I4ZHJFMm1GU3VlMDkxWWNsSzhMQlkybHBqbXJjUWNMZEd2YzNXVWdmdVltWFQ4UDRtWWJBS2MzZm9yaEpPWVExRzF3UmgwbmxETXVxTnE4ZkRpQUUtZw?oc=5","date":"2018-08-21","type":"pipeline","source":"Allied Market Research","summary":"China Oncology Drugs Market Size, Share and Analysis by 2026 | AMR - Allied Market Research","headline":"China Oncology Drugs Market Size, Share and Analysis by 2026 | AMR","sentiment":"neutral"}],"patents":[],"drugCount":21,"phaseCounts":{"phase_3":9,"phase_1":7,"phase_2":5},"enrichmentLevel":0,"visitCount":12,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}